Skip to main content
Clinical Trials/NCT05172284
NCT05172284Not yet recruitingNot Applicable

Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases (IMIDs) REMIND Study

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio1 site in 1 country2,000 target enrollmentStarted: February 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
2,000
Locations
1
Primary Endpoint
Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)

Study Overview

Brief Summary

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with a diagnosis of IMID.
  • Patients of any age, including minors.
  • Patients treated with approved medications for the condition in question and/or phototherapy.
  • Patients who agree to sign informed consent.

Exclusion Criteria

  • Patients without a diagnosis of IMID.
  • Patients who do not consent to sign informed consent.

Outcomes

Primary Outcomes

Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)

Time Frame: 15 years

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies.

Secondary Outcomes

  • PASI 75(15 years)
  • PASI 50(15 years)

Investigators

Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials